AbbVie
· ABBV
Rev. 1Y%
-6.44%
RPS 3Y CAGR
3.79%
RPS 10Y CAGR
10.02%
EPS 1Y%
-58.95%
EPS 3Y CAGR
-0.22%
EPS 10Y CAGR
0.57%
Gross Margin
80.33%
Op. Inc. Margin
30.23%
Profit Margin
9.23%
ROE
55.08%
ROA
3.61%
ROCE
16.78%
$0
359.54 B
70.18
-6.57
6.47
20.22
Competitive Advantages
Strong Immunology Franchise: Market-leading position in immunology treatment areas, including rheumatoid arthritis, Crohn's disease, and psoriasis.
Innovative New Products: Pipeline of promising new products, including Skyrizi and Rinvoq, with potential for significant market share gains.
Risks
Patent Expiration Risk: AbbVie's key products, Humira and Imbruvica, face patent expiration in the coming years, potentially reducing revenue.
Pricing Pressure: Increased competition from generics and biosimilars could put downward pressure on product prices, eroding margins.